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Abstract
Today, HIV-infected (HIV+) patients can be treated eﬃciently with combined antiretroviral
therapy (cART), leading to long-term suppression of viral load, in turn increasing life expec-
tancy. While cART reduced the occurrence of HIV-associated dementia, the prevalence of
subtle forms of HIV-associated neurocognitive disorders (HAND) is unchanged. This is related
to persistent immune activation within the CNS, which is not addressed by cART. Pathologic
processes leading to HAND consist of the release of proinﬂammatory cytokines, chemokines,
reactive oxygen metabolites and glutamate, and the release of HIV proteins. Some of those
processes can be targeted using medications with immunomodulatory and neuroprotective
properties such as dimethyl fumarate, teriﬂunomide, or minocycline. In this review, we will
summarize the knowledge about key pathogenic processes involved in HAND and potential
therapeutic avenues to target HAND.
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HIV-associated neurocognitive disorders (HAND) are alarm-
ing comorbidities in HIV-infected (HIV+) patients over long
term. The burden of HAND is more prevalent than is com-
monly known, with nearly every second HIV+ patient aﬀected
by HAND1,e1 (links.lww.com/NXI/A102). In an era of more
than 37million HIV+ patients worldwide,2 the potential impact
of HAND on society is alarming. Cognitive decline in HIV+
patients is associated with ﬁnancial diﬃculties, depressive and
anxiety symptoms, and unemployment.3 The introduction of
combined antiretroviral therapy (cART) in the mid-1990s
dramatically increased the life expectancy of HIV+ patients and
led to a phenotype shift of HAND. Today, the clinical pre-
sentation of the most severe phenotype, HIV-associated de-
mentia, is sparse because most patients are under eﬃcient
cART; however, there are more patients presenting with subtle
forms of the disease such as asymptomatic neurocognitive
impairment, associated with depression and insomnia.e2 As-
tonishingly, the overall prevalence of HAND has not been
inﬂuenced by the initiation of cART,4 which indicates that the
viral load is not the crucial driver for the development of
HAND. Moreover, evidence is increasing that self-fueling in-
ﬂammatory processes within the CNS drive neurodegeneration.
Targeting those inﬂammatory processes—independent of the
viral load—with immunomodulatory drugs additionally to cART
hence seems to be an interesting approach to reduce chronic
inﬂammation and maintain cognitive function in patients suf-
fering fromHAND. Keeping inmind the rising life expectancy of
HIV+ patients underlines the importance of understanding the
pathogenic mechanisms leading to cognitive impairment and
targeting a patient’s burdens with new treatment approaches.
In this review, we will discuss key pathogenic mechanisms and
potential therapeutic approaches with immunomodulatory
drugs, known from the treatment of neuro-inﬂammatory
diseases as potential therapeutic “add-on” to cART.
Pathologic processes driving HAND
Persistent immune activation in the CNS as
reason for neuronal loss
Infection of the CNS with HIV occurs through several mech-
anisms, such as transcytosis and the so called “Trojan Horse
Mechanism”, describing the diapedesis of HIV+ monocytes
over the blood-brain-barrier (BBB).e3 This process happens
during the ﬁrst 8 days of infection. Histopathologically, HIV
leads to encephalitis or leukoencephalopathy. Encephalitis is
characterized by the formation of multinucleated giant cells,
consisting of infected macrophages, disseminated inﬁltration
of lymphocytes, and macrophages.e4 Leukoencephalopathy
leads to loss of myelin in the white matter, astrocytosis, and
microglial inﬁltration.e5 Molecular processes fueling neuro-
degeneration are manifold and have therefore been described
as a dynamic puzzle.5 Besides, epidemiologic co-factors have
been connected toHAND. Cardiovascular disease, overweight,
diabetes, tobacco, alcohol, and drug abuse seem to promote
disease severity6,e6 as well as socio-economic factors, especially
educational level of the patientse7 and cART itself due to direct
neurotoxic eﬀects.7
Immune reactions and inﬂammatory changes form the funda-
ment of neuropathologic changes. Experiments with the
integrin-inhibitor natalizumab in rhesus macaques in a simian
immunodeﬁciency virus (SIV)-model underline the impor-
tance of infected monocytes and T-cells, which carry the virus
into the CNS.e8 Infected cells get recognized by glial cells in the
CNS and promote a persistent activation mainly of microglia
(summarized in Gonzalez-Scarano and Martin Garcia 2005).8
Because of the activation, proinﬂammatory mediators such as
cytokines, chemokines, reactive oxygen metabolites, and glu-
tamate increase in the CNS environment,e9–e11 which ulti-
mately leads to neurodegeneration.9,e12 Recent ﬁndings reveal
an induction of senescence-like phenotype ofmicroglia byHIV,
also associated with increased levels of reactive oxygen species
and proinﬂammatory cytokines.e13
Cytokines/chemokines
A key ﬁnding in HAND is the persistent release of chemo-
tactic and proinﬂammatory cytokines, considered as patho-
logic correlate of continuous inﬂammation. Deﬁning speciﬁc
biomarkers to predict HAND has fueled research eﬀorts.
Until now, a broad spectrum of cytokines elevated in the CSF
of HIV+ patients has been reported. This research is also
driven by the hope to establish biomarkers or a speciﬁc cy-
tokine pattern to determine whether patients are susceptible
to HAND and whether they might respond to treatment.
In HIV+ patients, pleocytosis leads to higher CSF levels of
interferon gamma (IFN-γ), TNF-α, IL-2, IL-6, IL-7, IL-8, and
IL-10.10 IFN-γ correlates with the severity of neurologic im-
pairment in HIV+ patients11 but is also elevated in HIV+
patients in the absence of clinical manifestations.e14 This
might indicate that IFN-γ is involved in the perpetuation of
HAND. Prolonged expression of IFN-γ reduces heme
oxygenase-1 expression in human astrocytes,12,e15 which is
known for its neuroprotective properties and its role in pre-
venting damage by oxidative stress.e16 This could, in part,
explain the role of IFN-γ as one of the key factors in driving
HAND.
Glossary
cART = combined antiretroviral therapy; CPE = CNS penetration eﬀectiveness; DMF = Dimethyl fumarate; HAND = HIV-
associated neurocognitive disorders; NF-kB = nuclear factor ĸß; PML = progressive multifocal leukoencephalopathy; RRMS =
relapsing-remitting MS; S1P1 = sphingosin-1 phosphate receptor 1; SIV = simian immunodeﬁciency virus.
2 Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 3 | May 2019 Neurology.org/NN
Polymorphisms in regulatory genes of cytokines and che-
mokines seem to be involved in the pathogenesis of HAND. A
polymorphism in the TNF-α gene is overexpressed in HIV+
patients aﬀected by dementia compared to HIV+ patients
without dementia.e17 Similar to this, a mutated CCL2-allel is
associated with a 4.5-fold higher risk to develop HIV-
associated dementia, whereas the same mutation lowers the
risk of getting infected with HIV.e18 Undoubtedly, one of the
most prominent mutations in the context of HIV+ andHAND
is the CCR5 delta32 mutation, which is the receptor of the
chemokine CCL5. A heterozygous genotype of this mutation
lowers the prevalence of HAND,e19 supporting the role of
chronic CNS inﬂammation for the development of HAND.
Histopathologic changes during HAND are characterized by
inﬁltrating immune cells. Chemokines play an important role in
guiding cells to the site of inﬂammation. CCL2 (monocyte
chemoattractant protein 1) is crucial for the transmigration of
HIV+ cells over the BBB.13 Another predominant chemokine in
HAND is CXCL10,14,15 which mainly recruits monocytes and
T-cells to the location of inﬂammation.e20,e21 In addition to its
chemoattractant properties, CXCL10 is described to induce
neurodegeneration via calcium dysregulation in the CNS.e22
The chemokine CCL5, a natural ligand of the HIV entry re-
ceptor CCR5 in monocytes, recruits monocytes to the site of
inﬂammation into the CNSe23 and is elevated in neuro-
psychologically asymptomatic HIV+ patients.14 The chemotac-
tic eﬀects on monocytes might increase the inﬂammatory state
in theCNS. Indeed, the co-culture ofHIV+monocytes ampliﬁes
the cytokine secretion of microglia in accordance with enhanced
neurotoxicity,14,15 supporting the idea that reducing chemotaxis
of monocytes might have positive eﬀects on neurodegeneration.
Results from SIV-infected rhesus macaques, focusing on
caspase-1 activation by SIV, show that cART is not suﬃcient to
suppress inﬂammation by immune cells16 in this context.
Similar to the pathogenesis of HAND, neurodegeneration
responsible for the progression in multiple sclerosis (MS) is
driven mostly by reactive oxygen species and soluble factors
instead of inﬁltrating immune cells. Soluble factors create an
environment known as “virtual hypoxia,” which drive neurons
into cell death (summarized in: Lassmann, 2018e24). It can be
considered as possible that in HAND also soluble factors are
the key factors for neurodegeneration or at least show neu-
rodegenerative potential.
In contrast to other neuroinﬂammatory diseases, the pathol-
ogy of HAND is also characterized by the involvement of viral
proteins, which trigger inﬂammation or induce neuro-
degeneration themselves.
HIV proteins
Even in HIV+ patients treated with cART with suppressed
systemic viral load, viral reservoirs in the CNS continue to
produce inﬂammatory mediators such as cytokines and che-
mokines. Viral proteins, which trigger neuroinﬂammation and
neurodegeneration themselvese25 are released by these viral
reservoirs as well. The most important viral protein in this
context is tat, which acts as a transactivator of transcription.e26
Tat is responsible for manifold processes on several cell types.
Tat increases the connexin43 (C ×43) expression by binding
to the C ×43 promotor,17 leading to an upregulated gap
junctional communication. This could lead to spreading of
pathologic signals from infected to uninfected astrocytes,
probably inositol trisphosphate 3–related and calcium-re-
lated.17 Blocking of HIV-tat release could therefore alter the
spreading of pathologic signals via gap-junction upregulation
and thus prevent apoptosis of uninfected astrocytes. Recently,
it was shown that tat provokes a change of the expression of
over 4,000 protein groups within neurons, and among other
factors reduces neuronal intrinsic excitability.e27 In line with
these ﬁndings, tat is able to reduce speciﬁc and presumably
vulnerable types of interneuronse28 and damages speciﬁcally
dopamine-rich regions of the CNS.e29 The deleterious eﬀects
of tat are supported by the eﬀect on microglial cells. Tat
promotes the secretion of various proinﬂammatory cytokines
and reactive oxygen species, which results in an enhanced rate
of neurotoxicity.e30,e31 In addition to tat, gp120 is another
viral protein, which is released by infected cells and is known
to induce an outward current of potassium from microglia.
This increase of extracellular potassium is crucial for neuro-
degeneration.18 Also, the regulatory protein nef generates
neuronal cell death, especially in combination with the che-
motactic cytokine CXCL10.e32
Those processes are linked to the development of energetic
failure, a process known from other neuroinﬂammatory
conditions with degenerative aspects such as MS. Using
a model of HIV-1 transgenic rats characterized by the ex-
pression of diﬀerent HIV-proteins revealed changes in mito-
chondrial proteins involved in electron transport chain, the
glycolytic pathways, and mitochondrial traﬃcking proteins.19
These changes correlate with a reduced function of mito-
chondria. Mitochondrio-protective strategies could hence
provide a potential approach to reduce energetic misbalances
and prevent neurodegeneration.
In summary, HIV infection of the CNS creates a proin-
ﬂammatory and neurotoxic environment, characterized by the
reproduction of HIV, the formation of multinucleated giant
cells, and the release of cytokines and HIV-proteins, driving
ongoing neurodegeneration. Addressing these neuro-
inﬂammatory processes in conjunction with antiretroviral
approaches might therefore target neurodegeneration.
New therapeutic approaches
For a long period of time, it was postulated that it might be
suﬃcient to reduce the CNS viral load to eﬃciently reduce
neurodegeneration and the occurrence of HAND. To de-
scribe the eﬀectiveness of antiretroviral therapies to penetrate
into the CNS, Letendre et al. deﬁned the CNS penetration
eﬀectiveness (CPE), consisting of 4 categories of eﬀectiveness
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to get into the CNS.e33 It was postulated that cART should
have high CPE scores in patients with neurocognitive im-
pairment. Until now, it is contradictory whether high CPE
might rather induce positive or negative eﬀects. A randomized
controlled trial showed slightly positive eﬀects in patients
treated with higher CPE.20 In contrast, retrospective analyses
done by the Antinori group showed that high CPE is corre-
lated with low performance in neuropsychologic tests.21
Hence, therapeutic approaches focusing only on a modiﬁca-
tion of cART regimen seem to be incomplete. One aspect,
which may confound CPE is the neurotoxic potential of some
antiretroviral substances. Efavirenz is known to cause neuro-
psychiatric side eﬀects such as dysphoric dreams. Thus, new
therapeutic approaches are urgently needed to improve cog-
nitive function in HIV-positive individuals. Several promising
antiinﬂammatory candidates are known from the treatment of
neuroinﬂammatory and neurodegenerative conditions and
will be reviewed in the context of HAND (therapeutic
approaches are summarized in ﬁgure).
Dimethyl fumarate
Dimethyl fumarate (DMF) has been licensed as medication for
relapsing-remittingMS (RRMS) in 2013 by the Food andDrug
Administration. The development of DMF has a history of
more than 50 years and was started in the 1950s when
Schweckendieck, aﬀected by psoriasis, treated himself with
fumarates. In 1994, Fumaderm was licensed in Germany as
therapy for psoriasis. Following ﬁrst reports about eﬃcacy in
coincidental MS, a prospective clinical observation showed
eﬃcacy in 10 RRMS patients over 72 weeks.e34 The pivotal
phase 3 clinical trial DEFINEe35 led to the approval as therapy
for RRMS. DMF has pleiotropic eﬀects. DMF modiﬁes the
kelch-like ECH-associated protein 1 pathway, which results in
upregulation of antioxidative genes.22 The molecule induces
a shift towards T-helper 2 cells,e36 decreases the number of
mature memory B cells,e37 and modulates microglia to a neu-
roprotective phenotype.e38. DMF treatment is associated with
lymphocytopenia (>30% decline of lymphocytes) because of
apoptosis in distinct T-cell subsets.e35,e39,e40 Therefore, it could
be argued that DMF therapy is not suitable for the treatment of
HIV+ patients, because one of the main treatment goals is to
keep the CD4 cell count as high as possible.23 Disregarding the
fact that DMF lowers the T-cell count, it holds some properties,
which are very promising in the context of HAND.
DMF inhibits the nuclear factor ĸß (NF-kB) pathway.e41 NF-
kB activation acts as a starting signal for HIV transcription,
which is sensed by viral long-terminal repeats.e42 HIV uses
activation of immune cells to reactivate from latency and start
transcription and—even with cART—low-level viral protein
production. Disturbing this ability of HIV to sense immune
cell activation could prevent ongoing and low-level neuro-
degeneration. In addition to this, tat increases transcriptional
activity of NF-kB, which leads to an increased immune cell
activation and together with the activity of nef, vpu, and env to
a repression of the CD4 receptor in infected cells.e43 In vitro
studies underline the putative role of DMF as add-on therapy
for patients with HAND.DMF induces antioxidant responses,
Figure Summary of potential treatment approaches for HAND
Shown are different treatment approaches for HAND targeting key pathogenic processes, involving blocking of lymphocyte trafficking into the CNS (A),
reduction ofmonocyte trafficking (B), modification of NFkß with reduced viral replication (C), and reduction ofmicroglial activation (D). Images weremodified
from Servier Medical Art, licensed under a creative common license. DMF = Dimethyl fumarate; HAND = HIV-associated neurocognitive disorders; NFkß =
nuclear factor ĸß
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suppresses HIV replication, and lowers neurotoxin release
from infected cells in a model of HIV+ monocyte-derived
macrophages.24 Our data indicate that DMF lowers the
amount of secreted chemokines in co-culture of microglial
cells with HIV-transduced monocytoid cells, which results
in signiﬁcantly decreased neuronal cell death in vitro.15
Summarizing, those data argue for a use of DMF in
HAND-aﬀected HIV+ patients. Because of the drawback of
lymphopenia and the risk of progressive multifocal leu-
koencephalopathy (PML), patients should be monitored
closely if treated in a clinical trial.
Fingolimod
Fingolimod targets the sphingosin-1 phosphate receptor 1
(S1P1) and is used as escalating therapy in RRMS.
Sphingosin-1 phosphate responsiveness is reduced in HIV+
patients, especially in immunologic nonresponders and seems
to be one of the driving factors of lymph node enlarge-
ment.25,e44 Of interest, S1P1 forms heteromers with the
CCR5 receptor, which is mainly responsible for HIV entry
into CD4+ T-cells and monocytes. Use of ﬁngolimod as an
agonist of S1P1 catalyzes internalization and degradation of
the receptor, which also aﬀects the CCR5-and the NF-kB
pathway. In the context of HIV infection, ﬁngolimod can
inhibit productive infection of systemic monocytes and es-
pecially in the immune-privileged CNS it acts as an HIV
latency reversing agent.26,e45 Because HIV uses microglia as
viral reservoir in the CNS, which produces constantly low
levels of viral proteins and proinﬂammatory factors, address-
ing these cells with a pharmacologic agent is of great inter-
est.e46 In vitro experiments reveal a decreased release of
neurotoxic metalloproteinase proteins after sphingosine-1-
phosphate directed treatment, which could also be re-
sponsible for reduced neurodegeneration.e47 In addition,
ﬁngolimod induces neuroprotective properties in a neuronal
progenitor cell line and upregulates glycolysis-related genes in
HIV-exposed neurons.e48 One drawback of a therapeutic
approach using ﬁngolimod is, similar to other immunomod-
ulatory drugs, that ﬁngolimod can induce lymphocytope-
nia,e49 arguing for close monitoring in case of a therapeutic
trial.
Teriflunomide
Teriﬂunomide is an oral ﬁrst-line treatment for RRMS. It
mediates an inhibitory eﬀect on the enzyme dihydroorotate
dehydrogenase and reduces the proliferation of B and
T cells.e50 Like ﬁngolimod and DMF, teriﬂunomide alters the
NF-kB pathway, which results in reduced secretion of
proinﬂammatory and neurotoxic agents (e.g., matrix metal-
loproteinases, IL-6, and CCL2).15,e51 We showed that teri-
ﬂunomide reduces microglia-mediated neurotoxicity in
vitro.15 The predecessor substance of teriﬂunomide, leﬂuno-
mide, shows antiviral properties in polyomavirus BK in-
fection.27 Therefore, teriﬂunomide was already used in a small
trial in HIV+ individuals.28 Treatment decreased in-
ﬂammation markers and reduced the number of circulating
CD4+ T cells, whereas na¨ıve and memory T-cell subsets were
not altered. Apoptosis of T cells also was not altered. Notably,
teriﬂunomide was used in cART na¨ıve HIV+ patients and only
for a short period of time, which limits the conclusions drawn
by this study.28 Moreover, there was no investigation of
neuropsychologic outcome after leﬂunomide therapy.
Natalizumab
Natalizumab is a monoclonal antibody directed against α4-
integrin, used for the treatment of RRMS as escalation ther-
apy. To reduce leukocyte traﬃcking into the CNS—and
therefore the inﬁltration of HIV+ inﬂammatory cells—
natalizumab was used in a SIV-macaque model. Natalizumab
treatment 28 days after infection led to stabilization of neu-
ronal injury, reduced numbers of monocytes/macrophages,
and reduced productive infection.e8 Early treatment at the
time of infection blocked monocyte traﬃcking and SIV-RNA
was not detectable in the CNS.e8 In a model of HIV-
associated neuropathy, SIV-infected macaques treated with
natalizumab had reduced dorsal root ganglion pathology with
decreased inﬂammation, neuronophagia, and Nageotte nod-
ules, indicating degeneration of ganglion cell bodies and
a reduced number of macrophages.29 CD3+ lymphocytes
were not aﬀected by natalizumab. Blocking traﬃcking of
monocytes/macrophages into the CNS by natalizumab could
be an interesting approach to reduce CNS viral load and
deleterious interaction of infected monocytes/macrophages
with microglia. However, the occurrence of PML, a feared
complication of both HIV-infection and long-term therapy in
natalizumab-treated MS patients, could limit the long-term
use in HIV-infected individuals. Moreover, a therapeutic ap-
proach could be limited to individuals in an early stage of
infection because the virus gets into the CNS within 8 days, as
reviewed above.
Interferons
Also because of antiviral activity, interferons were studied in
MS, leading to approval in the early 1990s. Although until
now numerous new therapeutic approaches have been
invented, interferons are still commonly used in MS ther-
apy.e52 In HIV infection, interferonmediators (e.g., CXCL10)
are upregulated early during disease progression,30 which can
also be found in asymptomatic HAND patients.14 In contrast
to previously mentioned treatments, interferons should be
used with caution in the context of HAND. Experiments in an
SIV model reveal pleiotropic eﬀects of interferons with
upregulation of antiviral genes on the one side and increased
depletion of CD4+ T-cells as well as increased SIV reservoir
size on the other side.31 Data from animal experiments in-
dicate a neurotoxic eﬀect of interferons on rat cortical neurons
and especially in a HAND-mouse model.32,33
Minocycline
Minocycline is an antibiotic used for the treatment of acne
vulgaris and in rheumatoid arthritis. Minocycline has been
shown to be eﬀective in several conditions such as clinically
isolated syndromee53 and models of progressive MS.34 Min-
ocycline reduces microglial activitye54,e55 and leukocyte
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traﬃcking into the CNS.e56 Themedicationmight also induce
neuroprotective properties in HAND. Minocycline was in-
vestigated in HIV-positive patients with cognitive impair-
ment. Seventy-three patients received either minocycline
100 mg bid or placebo. However, treatment over 24 weeks did
not improve cognitive function.35 Although those results were
disappointing, minocycline might induce subclinical, pro-
tective changes. In a phase 2 randomized placebo-controlled
study in 107HIV+ patients with cognitive impairment therapy
with either minocycline 100 mg bid or placebo over a period
of 24 weeks led to improvement of lipid and protein markers
of oxidative stress such as ceramides.36 Other markers such as
neuroﬁlament heavy chain levels did not diﬀer. Hence, it
might be worthwhile to test minocycline over a longer period.
It could be speculated that the interventional approach to
treat over 24 weeks might just be too short to detect positive
eﬀects.
Statins
Statins are used for their ability to lower cholesterol levels and
prevent cardiovascular diseases. In addition, statins show
immunomodulatory properties in the context of autoimmune
disease.37 Cardiovascular diseases are more prominent and
often connected to higher cholesterol levels in older HIV+
patients.e57,e58 Elevated cholesterol levels are correlated with
a faster rate of cognitive decline, which can be reduced by
statin use.e59 Statins can alter the proportion of monocytes
and additionally lower the expression of the chemokine
CCL2, responsible for the accumulation of monocytes in the
CNS during HAND progression.38,e60 However, a small study
in 7 HIV+ patients revealed no eﬀect of treatment with
atorvastatin over 8 weeks on CSF virologic and inﬂammatory
indices.39 Because of their eﬀect on monocytes and the pos-
itive eﬀects on the cardiovascular system, statins are never-
theless interesting potential therapeutic agents and should be
investigated in a larger clinical trial.
Data availability
Not applicable.
Conclusion
HIV+ can be treated eﬃciently with cART in the 21st cen-
tury, leading to nearly normal life expectancy. Associated
with this, clinicians face the challenge to optimize long-term
complications and help to increase quality of life of infected
patients, which is reduced in nearly every second HIV +
patient because of the occurrence of mostly subtle cognitive
alterations. While cART can alleviate the severity of HAND,
it does not aﬀect its prevalence, which indicates the impor-
tance of new therapeutic approaches to reduce the burden of
HAND (summarized in: Patel, 2018e61). Because of many
similarities between immune activation in HAND and MS
such as persistent immune activation with release of proin-
ﬂammatory cytokines, chemokines, and neurotoxic media-
tors, the translation of MS medications to HAND is obvious.
Moreover, other generic medications such as the antibiotic
minocycline or statins have properties, which could be ad-
vantageous to reduce persistent immune activation and
neurotoxicity. Several of the drugs reviewed target cellular
pathways, which are important for persistent CNS in-
ﬂammation and neurodegeneration (e.g., NFĸβ), which
makes them ideal candidates for co-treatment with standard
cART use.
One drawback of the aforementioned therapeutic approaches
is their eﬀect to reduce lymphocyte counts (e.g., DMF, ﬁn-
golimod, and natalizumab), which is critical in the context of
HIV treatment, because one of the main goals is to stabilize
the CD4 counts. This should be one great admonisher to
carefully check these drugs for their potential use in HAND
patients but should not act as a general obviation. Behavior of
the immune system within the CNS is not easy to predict, as
occurrence of HIV associated immune reconstitution in-
ﬂammatory syndrome points out. Up to 13% of the HIV+
patients are aﬀected after starting cART, evidencing that also
a recovery of the immune system and especially of CD4+
T-cells can cause issues within the CNS.40
In summary, we believe that HAND treatment could be op-
timized if experience with medications known from other
neuroinﬂammatory conditions would be translated into
a clinical trial in patients aﬀected by HAND.
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